RxDoctor Payments Data

Ruby Rodriguez

Family · San Antonio, TXNPI 1841950672

Payments from drug & device makers

$1,356in general payments, 2019–2025

Across 48 payments — averaging $28.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$429
  • Novo Nordisk$304
  • AstraZeneca$124
  • Otsuka America Pharmaceutical, Inc.$92
  • AbbVie$70
  • Dynavax Technologies Corporation$58
  • plus $280 from 10 others

What the payments were for

  • Food & beverage$1,356100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,356 in reported general payments places this provider in the 70th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$5,632
Medicare patients
49
Services billed
139

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide18$29,751
MounjaroTirzepatide20$20,767
Fluticasone Propionate66$1,328
Albuterol Sulfate HfaAlbuterol Sulfate40$923
Gabapentin39$832
Duloxetine Hcl21$562
Atorvastatin Calcium26$406
Montelukast Sodium36$370
Omeprazole19$369
Tizanidine Hcl57$312
Tramadol Hcl31$234
Vitamin D2Ergocalciferol (Vitamin D2)21$214
Nystatin14$192
Tamsulosin Hcl17$186
Metoprolol Succinate11$182

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$429$50,51838 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 15,456 family providers in Texas.

Other family in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →